Tag: human genome sequence

Illumina to Pay $1.2 Billion to Acquire Pacific Biosciences

IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion.

This deal will bolster Illumina’s already-dominant position in the market for DNA-sequencing machines. Wall Street analysts quickly pointed out that this gives Illumina control of two gene

View Article

May 06, 2013 “Intelligence: Late Breaking Lab News”

Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing a reference and esoteric anatomic pathology testing service with national ambitions. Within days of

View Article

How Digital Pathology Helps Pathologists Deliver Added Value

“Pathologists have the opportunity to take on a new clinical role as the integrator
of all that digital pathology information, in combination with the patient’s other clinical data collected from a wide variety of sources.”

—Dirk G. Soenksen, M.S., M.B.A., Founder and CEO, Aperio
CEO Summary: During the 1990s, the pathology profession was exploring ways to use telepathology

View Article

Whole Genome Sequencing: Is It Ready for Prime Time?

CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagnostic, therapeutic, and prognostic information they contain. GenomeQuest CEO Richard Resnick discusses what is required

View Article

“Primary-Care Pathology” One Goal at Beth Israel

CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annotation of the genetic data. BIDMC will analyze these whole human genome sequences to develop companion diagnostic tests

View Article

Clinical Labs and Whole Human Gene Sequencing

CLINICAL LABORATORY ADMINISTRATORS AND SENIOR EXECUTIVES would be well advised to pay close attention to our lead story about the whole human genome sequence collaboration just announced by the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQuest, Inc. (See pages 3-6.)

Together, the two organizations intend to be among the first in the

View Article

August 23, 2010 “Intelligence: Late Breaking Lab News”

With the goal of developing biomarkers useful in diagnosing a variety of cancers, Pathwork Diagnostics, Inc., and Novartis AG announced a research partnership on July 30. It is an early example of a collaboration between a diagnostics company and a pharmaceutical company for the specific purpose of producing assays for use as “companion diagnostics”— diagnostic

View Article